NIOX® Revenue
Medical Equipment Manufacturing • 
Edmund Halley Road, Oxford, United Kingdom • 101-200 Employees
NIOX® revenue & valuation
| Annual revenue | $32,500,000 |
| Revenue per employee | $248,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $103,900,000 |
| Total funding | $98,000,000 |
Key Contacts at NIOX®
Mark Vesey
Director, Americas Private Payor And Government Access
Chris Bushe
Medical Director Row Excluding Usa
Anthony Lubischer
Director, Research Business
Brian Mccrystal
Director, Us Commercial Operations
Rebecca Clayton-Wherity
Group Operational Finance Director
Sean Haines
Director - Distribution Business
Lee Sykes
Global It Operations Director
Company overview
| Headquarters | Edmund Halley Road, Oxford, England OX4 4GB, GB |
| Phone number | +441865405560 |
| Websites | |
| SIC | 382 |
| Keywords | Asthma Management, Niox®, Asthma Diagnosis, Feno Testing |
| Founded | 2006 |
| Employees | 101-200 |
| Socials |
NIOX® Email Formats
NIOX® uses 5 email formats. The most common is {first name}.{last name} (e.g., john.doe@circassia.com), used 44.8% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@circassia.com | 47.8% |
{first initial}.{last name} | j.doe@circassia.com | 49.2% |
{first initial} | j@circassia.com | 3% |
About NIOX®
NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma. NIOX VERO® provides accurate and reliable results, allowing healthcare professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings. The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals. Overall, NIOX Group plc is the global leader in FeNO testing, with a strong reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma. References: 1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218. 2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1 3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173. 4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. 5. NIOX®. Data on File; MKT-DOF-007.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
NIOX® has 47 employees across 9 departments.
Departments
Number of employees
NIOX® Tech Stack
Discover the technologies and tools that power NIOX®'s digital infrastructure, from frameworks to analytics platforms.
CDN
Security
Hosting
Ecommerce
JavaScript libraries
JavaScript libraries
Webmail
Programming languages
Analytics
UI frameworks
JavaScript libraries
Colombia
Spain
Bangladesh
LithuaniaFrequently asked questions
4.8
40,000 users
